Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1996-12-10
|
| pubmed:abstractText |
The effect of a local injection with a streptococcal preparation OK432 on the antitumor vaccination with tumor cells was investigated. Natural killer (NK) cells, which were detected by anti-NK1.1 monoclonal antibody (mAb), increased in the peritoneal exudate cells after an intraperitoneal (i.p.) injection with syngeneic B16 melanoma cells. Furthermore, a concurrent i.p. injection with OK432 efficiently sustained the locally infiltrating NK cells. The OK432 treatment also sustained the augmented NK and lymphokine-activated killer activities in the peritoneal exudate cells. This treatment also increased the ability of the locally infiltrating NK cells to produce interferon gamma in response to the tumor cells. In addition, the concurrent i.p. injection with OK432 in combination with the tumor cells enhanced the capacity of the spleen cells to turn into anti-(B16 melanoma) cytotoxic T lymphocytes after in vitro restimulation. This augmenting effect of OK432 was dependent on NK cells. Moreover, the concurrent injection with OK432 at the time of anti-tumor vaccination significantly enhanced the protective immunity against B16 melanoma at the rechallenge. Taken together, these findings indicate that a concurrent local injection with OK432 in combination with tumor cells efficiently augments the antitumor vaccination effect, in part, by sustaining the locally infiltrating activated NK cells.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0340-7004
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
43
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
31-8
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:8917633-Adoptive Transfer,
pubmed-meshheading:8917633-Animals,
pubmed-meshheading:8917633-Exudates and Transudates,
pubmed-meshheading:8917633-Female,
pubmed-meshheading:8917633-Injections, Intraperitoneal,
pubmed-meshheading:8917633-Interferon-gamma,
pubmed-meshheading:8917633-Killer Cells, Lymphokine-Activated,
pubmed-meshheading:8917633-Killer Cells, Natural,
pubmed-meshheading:8917633-Kinetics,
pubmed-meshheading:8917633-Melanoma, Experimental,
pubmed-meshheading:8917633-Mice,
pubmed-meshheading:8917633-Mice, Inbred C57BL,
pubmed-meshheading:8917633-Neoplasms,
pubmed-meshheading:8917633-Peritoneal Cavity,
pubmed-meshheading:8917633-Phenotype,
pubmed-meshheading:8917633-Picibanil,
pubmed-meshheading:8917633-Spleen,
pubmed-meshheading:8917633-Stimulation, Chemical,
pubmed-meshheading:8917633-T-Lymphocytes, Cytotoxic
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
The concurrent administration of OK432 augments the antitumor vaccination effect with tumor cells by sustaining locally infiltrating natural killer cells.
|
| pubmed:affiliation |
Department of Immunology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|